Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

NCT02507570 is registered in ClinicalTrials.gov with Carolina Research Professionals, LLC as lead sponsor.

NCT NCT02507570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02507570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
Lead sponsor
Carolina Research Professionals, LLC
Phase
Phase 2
Overall status
Completed
Start date
September 23, 2015
Completion date
January 18, 2019
Enrollment
40 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostate carcinoma metastatic to the bone